Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises un
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... second quarter ending June 30, 2015. ... We are excited to be near the completion of ... with topline results expected in the fourth quarter," stated ... Inc. "Translarna is now commercially available in 12 countries ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... 7, 2011 Cempra Pharmaceuticals, a developer of ... that intravenous (IV) solithromycin demonstrates excellent ... IV doses up to 800 mg.  Oral administration ... reported Phase 1 studies.  The presentation will be ...
... May 6, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, said today it ... 2011 Health Care Conference on Wednesday, May 11. ... will provide an update on the company, beginning at 8:40 ...
Cached Medicine Technology:Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 2Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 3Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 4Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 5Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 6Intravenous (IV) Administration of Cempra Pharmaceutical's Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial 7
(Date:8/1/2015)... ... 01, 2015 , ... On Tuesday, July 28th, Symantec released a security industry ... been behind the attack on Anthem Inc. which resulted in one of the largest ... attacks and spear phishing campaigns. , For Joe Caruso, founder and CEO/CTO ...
(Date:8/1/2015)... , ... August 01, 2015 , ... “ reTXT ” ... at the latest and coolest applications on the market for iOS, Android, and Windows. ... shared with viewers allows users to clarify, edit and delete any message including ones ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Ticket Down is a reputable source of ... the MGM Grand Garden Arena. Fans of every genre of music will have an ... 18th, the first day of the festival, the following artists will perform: Sam Smith, ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... new industry players to know in predictive health analytics , Jvion continues ... technologies. The firm creates predictive software that targets patient and population level illness ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2
... ,Think About Their Drink, CHICAGO, Oct. 29 , WHO: The ... About Your Drink Family Challenge among hundreds of ... Kading family entered the photo contest by submitting a ... part of a nationwide education campaign, the ...
... Spear,s ,Toxic, Diet Causing Her Erratic Behavior?, LOS ... young Hollywood stars are imploding. Spears and others are ... fast,food. No doubt a host of issues may be ... diet of many celebrities can cause big problems. ...
... to lab tests, interpreting the clinical importance of an ... has, suggests research from the Johns Hopkins Childrens Center. ... of Pediatrics Conference Oct. 26 through Oct. 30 in ... residents, six fellows and 10 senior attending physicians in ...
... & Science University Cancer Institute researchers have found that ... their backs is a better method for delivering radiation ... to reproduce ,the positioning of the patient allowed more ... a surprising finding, according to according to Martin Fuss, ...
... in access to health care and education hinder ... cancer services and often lead to delayed cancer ... education geared toward African-Americans, researchers with the University ... The Centers for Healthy Hearts and Souls, a ...
... DHAKA, Bangladesh, Oct. 28 Therap Services will ... be held on November 6 - 8, 2007 ... World Health Organization, has set the,theme "Resources and ... as a gold sponsor. Therap Services will ...
Cached Medicine News:Health News:MilkPEP: Chicago Area Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: Chicago Area Family Wins Nationwide got milk? Contest 3Health News:Bestselling Author Dr. Timothy Brantley Explains the Connection of Food and Mood 2Health News:What is a critical lab value? it depends, Hopkins researchers find 2Health News:Positioning pelvic cancer patients on stomachs for radiation yields better results 2Health News:Education program leads to lasting improvement of cancer knowledge in African Americans 2Health News:Therap Services to Attend 2nd International Conference on Intellectual Disabilities/Mental Retardation as Gold Sponsor 2
... The A5500 is an extremely accurate ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, large 7 CRT monitor, built-in thermal ...
... most advanced IOL workstation. Accurate, efficient and ... be used with a variety of regressive, ... to the needs of the patient. Convenient ... a foot pedal for hands-free operation, audible ...
... unit with graphic display and IOL power ... units include firmware module with SRK II, ... All model DGH 5000e and DGH 5100e ... reducing the possibility of short readings. The ...
The UD-1000 incorporates the latest ultrasound technology for eyecare specialists. It is the ideal choice for your modern diagnostic laboratory. The UD-1000 combines a powerful B-sector scan system w...
Medicine Products: